Ascentage Pharma Group International (NASDAQ:AAPG) Rating Increased to Strong-Buy at BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by stock analysts at BTIG Research to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other equities research analysts have also weighed in on AAPG. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a report on Monday, November 24th. Oppenheimer started coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $48.00.

Ascentage Pharma Group International Trading Up 1.8%

Shares of AAPG stock opened at $24.43 on Wednesday. The stock has a fifty day moving average of $25.05 and a 200 day moving average of $31.18. Ascentage Pharma Group International has a 52 week low of $17.56 and a 52 week high of $48.45. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ascentage Pharma Group International in the third quarter worth $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth about $204,000. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the 3rd quarter worth about $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, Tema Etfs LLC bought a new stake in Ascentage Pharma Group International during the 2nd quarter valued at about $610,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.